Randomized-Controlled Trial to Compare the Efficacy of Andrographis paniculata Powder and Favipiravir for the Treatment of Mild COVID-19
Puriwatthanapong et al., Journal of Thai Traditional & Alternative Medicine, 21:3
RCT 231 mild COVID-19 outpatients in Thailand comparing Andrographis paniculata (AP) extract in two forms versus favipiravir, showing no significant differences between groups. Patients were randomized to either aerial parts AP extract (n=77), AP leaf extract (n=77), or favipiravir (n=77) for 5 days. There was no control group. There were no significant differences between groups in progression to pneumonia, clinical severity changes, or viral clearance at days 5 and 10. Authors suggest that AP extracts may be as effective as favipiravir for mild COVID-19 and note AP's lower cost.
Puriwatthanapong et al., 29 Dec 2023, Randomized Controlled Trial, Thailand, peer-reviewed, 14 authors.
